The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction.


Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
09 2019
Historique:
received: 22 05 2019
revised: 10 06 2019
accepted: 27 06 2019
pubmed: 26 7 2019
medline: 21 5 2020
entrez: 26 7 2019
Statut: ppublish

Résumé

Faecal calprotectin decreases during exclusive enteral nutrition in children with active Crohn's disease. It is unknown how faecal calprotectin changes during food re-introduction and the influence of maintenance enteral nutrition. To study changes to faecal calprotectin during exclusive enteral nutrition and at food reintroduction, and explore associations with maintenance enteral nutrition. Children with Crohn's disease were followed during exclusive enteral nutrition and during food-reintroduction. Faecal calprotectin was measured before, at 33 and 54 days of exclusive enteral nutrition, and at 17, 52 and 72 days after food-reintroduction. Maintenance enteral nutrition use was recorded with estimated weight food diaries. Data are presented with medians and Q1:Q3. Sixty-six patients started exclusive enteral nutrition and 41 (62%) achieved clinical remission (weighted paediatric Crohn's disease activity index <12.5). Baseline faecal calprotectin (mg/kg) decreased after 4 and 8 weeks of exclusive enteral nutrition (Start: 1433 [Q1: 946, Q3: 1820] vs 33 days: 844 [314, 1438] vs 54 days: 453 [165, 1100]; P < .001). Within 17 days of food reintroduction, faecal calprotectin increased to 953 [Q1: 519, Q3: 1611] and by 52 days to 1094 [660, 1625] (both P < .02). Fifteen of 41 (37%) children in remission used maintenance enteral nutrition (333 kcal or 18% of energy intake). At 17 days of food reintroduction, faecal calprotectin was lower in maintenance enteral nutrition users than non-users (651 [Q1: 271, Q3: 1781] vs 1238 [749, 2102], P = .049) and correlated inversely with maintenance enteral nutrition volume (rho: -0.573, P = .041), kcals (rho: -0.584, P = .036) and % energy intake (rho: -0.649, P = .016). Maintenance enteral nutrition use was not associated with longer periods of remission (P = .7). Faecal calprotectin at the end of exclusive enteral nutrition did not predict length of remission. The effect of exclusive enteral nutrition on faecal calprotectin is diminished early during food reintroduction. Maintenance enteral nutrition at ~18% of energy intake is associated with a lower faecal calprotectin at the early phase of food reintroduction but is ineffective in maintaining longer term remission.

Sections du résumé

BACKGROUND
Faecal calprotectin decreases during exclusive enteral nutrition in children with active Crohn's disease. It is unknown how faecal calprotectin changes during food re-introduction and the influence of maintenance enteral nutrition.
AIMS
To study changes to faecal calprotectin during exclusive enteral nutrition and at food reintroduction, and explore associations with maintenance enteral nutrition.
METHODS
Children with Crohn's disease were followed during exclusive enteral nutrition and during food-reintroduction. Faecal calprotectin was measured before, at 33 and 54 days of exclusive enteral nutrition, and at 17, 52 and 72 days after food-reintroduction. Maintenance enteral nutrition use was recorded with estimated weight food diaries. Data are presented with medians and Q1:Q3.
RESULTS
Sixty-six patients started exclusive enteral nutrition and 41 (62%) achieved clinical remission (weighted paediatric Crohn's disease activity index <12.5). Baseline faecal calprotectin (mg/kg) decreased after 4 and 8 weeks of exclusive enteral nutrition (Start: 1433 [Q1: 946, Q3: 1820] vs 33 days: 844 [314, 1438] vs 54 days: 453 [165, 1100]; P < .001). Within 17 days of food reintroduction, faecal calprotectin increased to 953 [Q1: 519, Q3: 1611] and by 52 days to 1094 [660, 1625] (both P < .02). Fifteen of 41 (37%) children in remission used maintenance enteral nutrition (333 kcal or 18% of energy intake). At 17 days of food reintroduction, faecal calprotectin was lower in maintenance enteral nutrition users than non-users (651 [Q1: 271, Q3: 1781] vs 1238 [749, 2102], P = .049) and correlated inversely with maintenance enteral nutrition volume (rho: -0.573, P = .041), kcals (rho: -0.584, P = .036) and % energy intake (rho: -0.649, P = .016). Maintenance enteral nutrition use was not associated with longer periods of remission (P = .7). Faecal calprotectin at the end of exclusive enteral nutrition did not predict length of remission.
CONCLUSIONS
The effect of exclusive enteral nutrition on faecal calprotectin is diminished early during food reintroduction. Maintenance enteral nutrition at ~18% of energy intake is associated with a lower faecal calprotectin at the early phase of food reintroduction but is ineffective in maintaining longer term remission.

Identifiants

pubmed: 31342536
doi: 10.1111/apt.15425
pmc: PMC6772069
doi:

Substances chimiques

Leukocyte L1 Antigen Complex 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

664-674

Subventions

Organisme : Natural Environment Research Council
ID : NE/L011956/1
Pays : International
Organisme : Engineering and Physical Sciences Research Council
Pays : International
Organisme : Nestle Health Science
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors. Alimentary Pharmacology & Therapeutics Published by John Wiley & Sons Ltd.

Références

Dig Dis Sci. 2013 Dec;58(12):3584-91
pubmed: 24026403
J Crohns Colitis. 2014 Oct;8(10):1179-207
pubmed: 24909831
J Clin Gastroenterol. 2011 Mar;45(3):234-9
pubmed: 20871409
J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):795-806
pubmed: 24231644
Aliment Pharmacol Ther. 2001 Apr;15(4):463-73
pubmed: 11284774
Front Pediatr. 2017 Jan 25;5:7
pubmed: 28180127
Cochrane Database Syst Rev. 2018 Apr 01;4:CD000542
pubmed: 29607496
J Gastroenterol. 2014 Apr;49(4):638-45
pubmed: 23636735
J Gastroenterol Hepatol. 2006 Oct;21(10):1609-14
pubmed: 16928225
Arch Dis Child. 2006 May;91(5):426-32
pubmed: 16632672
Aliment Pharmacol Ther. 2000 Mar;14(3):281-9
pubmed: 10735920
J Pediatr Gastroenterol Nutr. 2000 Jul;31(1):8-15
pubmed: 10896064
Gastroenterology. 2019 Apr;156(5):1354-1367.e6
pubmed: 30550821
Cell Host Microbe. 2015 Oct 14;18(4):489-500
pubmed: 26468751
Acta Paediatr. 2018 Dec;107(12):2199-2206
pubmed: 30192409
Gut. 1996 Apr;38(4):543-8
pubmed: 8707085
Aliment Pharmacol Ther. 2006 Nov 1;24(9):1333-40
pubmed: 17059514
Can J Gastroenterol Hepatol. 2017;2017:5873158
pubmed: 28567370
Inflamm Bowel Dis. 2012 Jan;18(1):55-62
pubmed: 21351206
J Allergy Clin Immunol. 2016 Aug;138(2):592-6
pubmed: 26987574
Inflamm Bowel Dis. 2012 Feb;18(2):246-53
pubmed: 21425210
Aliment Pharmacol Ther. 2013 Mar;37(6):622-9
pubmed: 23360085
Scand J Gastroenterol. 2001 Apr;36(4):383-8
pubmed: 11336163
Am J Gastroenterol. 2015 Dec;110(12):1718-29; quiz 1730
pubmed: 26526081
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1119-1120
pubmed: 29105140
Dig Dis Sci. 2012 Aug;57(8):2171-7
pubmed: 22661250
Acta Paediatr. 2018 Jan;107(1):156-162
pubmed: 28901585
J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):150-5
pubmed: 21788755
Inflamm Bowel Dis. 2011 Jun;17(6):1314-21
pubmed: 21560194
Scand J Gastroenterol. 2006 Jun;41(6):720-5
pubmed: 16716972
Dig Liver Dis. 2012 Aug;44(8):649-54
pubmed: 22542605
Inflamm Bowel Dis. 2014 Feb;20(2):278-85
pubmed: 24390062
Aliment Pharmacol Ther. 2019 Sep;50(6):664-674
pubmed: 31342536
J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):e112-e115
pubmed: 27540707
BMC Gastroenterol. 2014 Mar 20;14:50
pubmed: 24645851
Clin Transl Gastroenterol. 2015 Jan 15;6:e71
pubmed: 25588524
Cochrane Database Syst Rev. 2018 Aug 11;8:CD005984
pubmed: 30098021
Isr Med Assoc J. 2008 Jul;10(7):503-7
pubmed: 18751627
Clin Nutr. 2005 Oct;24(5):775-9
pubmed: 15904998
Dig Liver Dis. 2006 Jun;38(6):381-7
pubmed: 16301010
Aliment Pharmacol Ther. 2007 Jan 1;25(1):67-72
pubmed: 17229221
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005984
pubmed: 17636816
Appetite. 2015 Dec;95:36-43
pubmed: 26119811
Dig Dis Sci. 1993 Sep;38(9):1614-8
pubmed: 8359072
JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4 Suppl):S173-5; discussion S175-8, S184-8
pubmed: 15980280
Dig Liver Dis. 2000 Dec;32(9):769-74
pubmed: 11215556
J Gastroenterol. 2010;45(1):24-9
pubmed: 19798465
Aliment Pharmacol Ther. 2009 Sep 1;30(5):501-7
pubmed: 19549288
Inflamm Bowel Dis. 2015 Jun;21(6):1386-91
pubmed: 25851564
Scand J Gastroenterol. 2005 Dec;40(12):1431-7
pubmed: 16316891

Auteurs

Michael Logan (M)

Civil Engineering, School of Engineering, University of Glasgow, Glasgow, UK.
Human Nutrition, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

Clare M Clark (CM)

Human Nutrition, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

Umer Zeeshan Ijaz (UZ)

Civil Engineering, School of Engineering, University of Glasgow, Glasgow, UK.

Lisa Gervais (L)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Hazel Duncan (H)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Vikki Garrick (V)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Lee Curtis (L)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Elaine Buchanan (E)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Tracey Cardigan (T)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Lawrence Armstrong (L)

Department of Paediatrics, Crosshouse Hospital, Kilmarnock, UK.

Caroline Delahunty (C)

Department of Paediatrics, Wishaw General Hospital, Wishaw, UK.

Diana M Flynn (DM)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Andrew R Barclay (AR)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Rachel Tayler (R)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Elizabeth McDonald (E)

Institute for Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Simon Milling (S)

Institute for Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Richard K Hansen (RK)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Konstantinos Gerasimidis (K)

Human Nutrition, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

Richard K Russell (RK)

Department of Paediatric Gastroenterology, Royal Hospital for Children, Glasgow, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH